Abstract
Aims/hypothesis
Orexin A (OXA) modulates food intake, energy expenditure, and lipid and glucose metabolism. OXA regulates the secretion of insulin and glucagon, while glucose regulates OXA release. Here, we evaluate the role of glucagon in regulating OXA release both in vivo and in vitro.
Methods
In a double-blind crossover study, healthy volunteers and type 1 diabetic patients received either intramuscular glucagon or placebo. Patients newly diagnosed with type 2 diabetes underwent hyperinsulinaemic–euglycaemic clamp experiments, and insulin–hypoglycaemia tests were performed on healthy volunteers. The primary endpoint was a change in OXA levels after intramuscular glucagon or placebo administration in healthy participants and patients with type 1 diabetes. Secondary endpoints included changes in OXA in healthy participants during insulin tolerance tests and in patients with type 2 diabetes under hyperinsulinaemic–euglycaemic conditions. Participants and staff conducting examinations and taking measurements were blinded to group assignment. OXA secretion in response to glucagon treatment was assessed in healthy and obese mice, the streptozotocin-induced mouse model of type 1 diabetes, and isolated rat pancreatic islets.
Results
Plasma OXA levels declined in lean volunteers and in type 1 diabetic patients injected with glucagon. OXA levels increased during hyperinsulinaemic hypoglycaemia testing in healthy volunteers and during hyperinsulinaemic euglycaemic conditions in type 2 diabetic patients. Plasma OXA concentrations in healthy lean and obese mice and in a mouse model of type 1 diabetes were lower after glucagon treatment, compared with vehicle control. Glucagon decreased OXA secretion from isolated rat pancreatic islets at both low and high glucose levels. OXA secretion declined in pancreatic islets exposed to diazoxide at high and low glucose levels, and after exposure to an anti-insulin antibody. Glucagon further reduced OXA secretion in islets pretreated with diazoxide or an anti-insulin antibody.
Conclusions/interpretation
Glucagon inhibits OXA secretion in humans and animals, irrespective of changes in glucose or insulin levels. Through modifying OXA secretion, glucagon may influence energy expenditure, body weight, food intake and glucose metabolism.
Similar content being viewed by others
Abbreviations
- BW:
-
Body weight
- DIO:
-
Diet-induced obesity
- LP:
-
Healthy lean participants
- OXA:
-
Orexin A
- OXR:
-
Orexin receptor
- PKA:
-
Protein kinase A
- STZ-DM:
-
Streptozotocin-induced insulinopenic diabetes
References
Sakurai T, Amemiya A, Ishii M et al (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
Hara J, Beuckmann CT, Nambu T et al (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345–354
Hara J, Yanagisawa M, Sakurai T (2005) Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 380:239–242
Funato H, Tsai AL, Willie JT et al (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 9:64–76
Sellayah D, Bharaj P, Sikder D (2011) Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab 14:478–490
de Lecea L, Kilduff TS, Peyron C et al (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95:322–327
Marcus JN, Aschkenasi CJ, Lee CE et al (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6–25
Nakabayashi M, Suzuki T, Takahashi K et al (2003) Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol 205:43–50
Blanco M, Lopez M, Garcia-Caballero T et al (2001) Cellular localization of orexin receptors in human pituitary. J Clin Endocrinol Metab 86:1616–1619
Johren O, Bruggemann N, Dendorfer A, Dominiak P (2003) Gonadal steroids differentially regulate the messenger ribonucleic acid expression of pituitary orexin type 1 receptors and adrenal orexin type 2 receptors. Endocrinology 144:1219–1225
Rodgers RJ, Halford JC, Nunes de Souza RL et al (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13:1444–1452
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
Nishino S, Ripley B, Overeem S et al (2001) Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50:381–388
Peyron C, Faraco J, Rogers W et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
Siegel JM, Moore R, Thannickal T, Nienhuis R (2001) A brief history of hypocretin/orexin and narcolepsy. Neuropsychopharmacology 25:S14–S20
Honda Y, Doi Y, Ninomiya R, Ninomiya C (1986) Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9:254–259
Sakurai T (2005) Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 9:231–241
Tsuneki H, Murata S, Anzawa Y et al (2008) Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 51:657–667
Tsuneki H, Sugihara Y, Honda R, Wada T, Sasaoka T, Kimura I (2002) Reduction of blood glucose level by orexins in fasting normal and streptozotocin-diabetic mice. Eur J Pharmacol 448:245–252
Harada S, Yamazaki Y, Tokuyama S (2013) Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. J Pharmacol Exp Ther 344:276–285
Shiuchi T, Haque MS, Okamoto S et al (2009) Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 10:466–480
Ducroc R, Voisin T, El Firar A, Laburthe M (2007) Orexins control intestinal glucose transport by distinct neuronal, endocrine, and direct epithelial pathways. Diabetes 56:2494–2500
Skrzypski M, Le TT, Kaczmarek P et al (2011) Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetologia 54:1841–1852
Switonska MM, Kaczmarek P, Malendowicz LK, Nowak KW (2002) Orexins and adipoinsular axis function in the rat. Regul Pept 104:69–73
Nowak KW, Strowski MZ, Switonska MM et al (2005) Evidence that orexins A and B stimulate insulin secretion from rat pancreatic islets via both receptor subtypes. Int J Mol Med 15:969–972
Goncz E, Strowski MZ, Grotzinger C et al (2008) Orexin-A inhibits glucagon secretion and gene expression through a Fox01-dependent pathway. Endocrinology 149:1618–1626
Ehrstrom M, Naslund E, Levin F et al (2004) Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. Regul Pept 119:209–212
Ouedraogo R, Naslund E, Kirchgessner AL (2003) Glucose regulates the release of orexin-a from the endocrine pancreas. Diabetes 52:111–117
Consoli A (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430–441
Komaki G, Matsumoto Y, Nishikata H et al (2001) Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144:645–651
Arafat AM, Kaczmarek P, Skrzypski M et al (2013) Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia 56:588–597
Arafat MA, Otto B, Rochlitz H et al (2005) Glucagon inhibits ghrelin secretion in humans. Eur J Endocrinol 153:397–402
Arafat AM, Perschel FH, Otto B et al (2006) Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. J Clin Endocrinol Metab 91:3528–3533
Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397
Skrzypski M, Kakkassery M, Mergler S et al (2013) Activation of TRPV4 channel in pancreatic INS-1E beta cells enhances glucose-stimulated insulin secretion via calcium-dependent mechanisms. FEBS Lett 587:3281–3287
Dostmann WR (1995) (RP)-cAMPS inhibits the cAMP-dependent protein kinase by blocking the cAMP-induced conformational transition. FEBS Lett 375:231–234
Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA (1986) Diazoxide in the management of patients with insulinoma. World J Surg 10:586–592
Trube G, Rorsman P (1986) Calcium and potassium currents recorded from pancreatic beta-cells under voltage clamp control. Adv Exp Med Biol 211:167–175
Gilon P, Henquin JC (1992) Influence of membrane potential changes on cytoplasmic Ca2+ concentration in an electrically excitable cell, the insulin-secreting pancreatic B cell. J Biol Chem 267:20713–20720
Urdanivia E, Pek S, Santiago JC (1979) Inhibition of glucagon secretion by diazoxide in vitro. Diabetes 28:26–31
Cherrington AD (1997) The metabolic actions of glucagon. In: Draznin B, Rizza E (eds) Clinical research in diabetes and obesity, volume 1: methods, assessment, and metabolic regulation (contemporary biomedicine), 1st edn. Humana Press, Totowa, p 222
Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V (1992) Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 262:R975–R980
Geary N (1990) Pancreatic glucagon signals postprandial satiety. Neurosci Biobehav Rev 14:323–338
Vanderweele DA, Macrum BL, Oetting RL (1986) Glucagon, satiety from feeding and liver/pancreatic interactions. Brain Res Bull 17:539–543
Acknowledgements
We thank S. Hornemann from the German Institute of Human Nutrition Potsdam-Rehbruecke for her contribution to the collection of human data. We thank K. Sprengel from the German Institute of Human Nutrition, Potsdam-Rehbruecke, and A. Schönknecht and P. Exner from Charité-University Medicine Berlin for excellent technical assistance.
Funding
This study was supported by the German Diabetes Foundation (Deutsche Diabetes Stiftung; MZS and AMA), Deutsche Forschungsgemeinschaft (DFG; STR558; MZS), and the DFG-graduate school (GK1208; AMA). The study was also partially supported by the Polish National Science Centre (Narodowe Centrum Nauki; grant no. N N311 508339). MSk and PKa were supported by the Polish National Science Centre (grant no. 2011/03/N/NZ4/02965).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript
Author contributions
AMA, MZS, PKa and MSk designed the study, acquired the data and wrote the manuscript. AFHP, BW and KWN contributed to the study design and reviewed, edited and critically revised the manuscript. AA, SR, EP-O, PKo, MSa, DS and MB discussed the study design, collected and analysed the data, and edited and reviewed the manuscript. All authors gave final approval for the current version to be published. AMA and MZS take full responsibility for the content of the article.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM Table 1
(PDF 61 kb)
Rights and permissions
About this article
Cite this article
Arafat, A.M., Kaczmarek, P., Skrzypski, M. et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 57, 2108–2116 (2014). https://doi.org/10.1007/s00125-014-3335-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-014-3335-4